What is he best known for?
The fields of study he is best known for:
- Immune system
- Internal medicine
- Gene
Thomas W. Klein mainly investigates Immunology, Pharmacology, Immune system, Cannabinoid and Cytokine.
His studies in Immunology integrate themes in fields like Natural killer cell and Interleukin 12.
His Pharmacology research is multidisciplinary, incorporating perspectives in Delta-9-tetrahydrocannabinol, Innate immunology, Bioinformatics, Toxicity and Nicotine.
His study focuses on the intersection of Cannabinoid and fields such as Endocannabinoid system with connections in the field of Cannabinoid receptor type 2 and GPR18.
His Cytokine research includes themes of Tumor necrosis factor alpha, Endothelial stem cell, Legionella pneumophila, Microbiology and Macrophage.
His Microbiology research focuses on In vitro and how it connects with Cell and Cancer research.
His most cited work include:
- Cannabinoid-based drugs as anti-inflammatory therapeutics (549 citations)
- The cannabinoid system and immune modulation (438 citations)
- Randomized controlled trial of mindfulness-based stress reduction (MBSR) for survivors of breast cancer (366 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Microbiology, Immunology, Legionella pneumophila, Immune system and Cytokine.
His Microbiology research includes elements of In vitro, Macrophage, Legionella, Lipopolysaccharide and Antigen.
His work deals with themes such as Cannabinoid, Pharmacology and Cannabinoid receptor, which intersect with Immunology.
Thomas W. Klein has included themes like Molecular biology and Endocannabinoid system in his Cannabinoid study.
His Immune system research is multidisciplinary, incorporating elements of Drugs of abuse and Virology.
His study looks at the relationship between Cytokine and topics such as Tumor necrosis factor alpha, which overlap with Proinflammatory cytokine.
He most often published in these fields:
- Microbiology (39.04%)
- Immunology (34.59%)
- Legionella pneumophila (30.14%)
What were the highlights of his more recent work (between 2007-2020)?
- Pharmacology (17.47%)
- Linagliptin (5.14%)
- Internal medicine (12.33%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Pharmacology, Linagliptin, Internal medicine, Dipeptidyl peptidase-4 and Immunology.
His Internal medicine research focuses on Endocrinology and how it relates to Proinflammatory cytokine and Inflammation.
The study incorporates disciplines such as Oncology, Mindfulness-based stress reduction and Cannabinoid receptor in addition to Immunology.
His studies deal with areas such as Cannabinoid, Cellular differentiation and CXCR4 as well as Cannabinoid receptor.
His biological study deals with issues like Endogeny, which deal with fields such as Cytokine.
His Cytokine study frequently draws connections to other fields, such as Microbiology.
Between 2007 and 2020, his most popular works were:
- Randomized controlled trial of mindfulness-based stress reduction (MBSR) for survivors of breast cancer (366 citations)
- The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Attenuates Inflammation and Accelerates Epithelialization in Wounds of Diabetic ob/ob Mice (63 citations)
- Cannabinoid receptor 2 (CB2) mediates immunoglobulin class switching from IgM to IgE in cultures of murine-purified B lymphocytes. (49 citations)
In his most recent research, the most cited papers focused on:
- Immune system
- Internal medicine
- Gene
Internal medicine, Endocrinology, Immunology, Cannabinoid receptor type 2 and Pharmacology are his primary areas of study.
He combines subjects such as Proinflammatory cytokine, Receptor and Transcription factor with his study of Endocrinology.
Thomas W. Klein merges many fields, such as Immunology and Breast cancer, in his writings.
His Cannabinoid receptor type 2 study necessitates a more in-depth grasp of Cannabinoid receptor.
His biological study spans a wide range of topics, including CD14, CD163, Cellular differentiation and CXCR4.
His Pharmacology research is multidisciplinary, incorporating perspectives in Lipopolysaccharide, Stimulation, MAPK/ERK pathway and Monocyte.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
